Kinnate Biopharma announces 70% layoffs and pipeline restructuring
The company will suspend the development of three assets, considering strategic alternatives for two clinical programmes.
The company will suspend the development of three assets, considering strategic alternatives for two clinical programmes.
What's Your Reaction?
